Literature DB >> 27922981

Second Opinion Expert Pathology in Endometrial Cancer: Potential Clinical Implications.

Friederike Grevenkamp1, Felix Kommoss, Friedrich Kommoss, Sigurd Lax, Falko Fend, Diethelm Wallwiener, Birgitt Schönfisch, Bernhard Krämer, Sara Y Brucker, Florin-Andrei Taran, Annette Staebler, Stefan Kommoss.   

Abstract

OBJECTIVE: In cancer patients, the pathology report serves as an important basis for treatment. Therefore, a correct cancer diagnosis is crucial, and diagnostic discrepancies may be of clinical relevance. It was the aim of this study to perform a specialized histopathology review and to investigate potential clinical implications of expert second opinion pathology in endometrial cancer.
METHODS: Patients treated for endometrial carcinoma at the Tübingen University Women's hospital between 2003 and 2013 were identified. Original pathology reports were reviewed, and contributing pathologists were asked to submit original slides and paraffin blocks. Case review was subsequently performed by 3 pathologists specialized in gynecological pathology who were blinded for clinical information. For histological typing, the World Health Organization 2014 classification was used, grading and staging were performed according to International Federation of Gynecology and Obstetrics 2009. Risk assignment was performed based on the 2013 European Society for Medical Oncology clinical practice guidelines.
RESULTS: In 565 of 745 cases, which had originally been diagnosed as endometrial carcinoma, archival histological slides and blocks were available. In 55 (9.7%) of 565 cases, a major diagnostic discrepancy of potential clinical relevance was found after expert review. In 38 of these 55 cases, the diagnostic discrepancy was related to tumor type (n = 24), grade (n = 10) or myoinvasion (n = 4). In 17 cases, the diagnosis of endometrial carcinoma could not be confirmed (atypical hyperplasia, n = 10; endometrial carcinosarcoma, n = 4; neuroendocrine carcinoma, n = 1; leiomyosarcoma, n = 1; atypical polypoid adenomyoma, n = 1). Minor discrepancies not changing risk classification were also noted in 214 (37.9%) of 565, most frequently for grade within the low-grade (G1/G2) category (n = 184).
CONCLUSIONS: A retrospective gynecopathological case review was shown to reveal limited but significant discrepancies in histological diagnoses as well as typing and grading of endometrial carcinomas, some directly impacting clinical management. Second opinion pathology therefore not only helps to improve the quality of translational research study cohorts but might also help to optimize patient care in difficult cases.

Entities:  

Mesh:

Year:  2017        PMID: 27922981     DOI: 10.1097/IGC.0000000000000870

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.

Authors:  Stefan Kommoss; Andreas D Hartkopf; Bernhard Krämer; Anne-Kathrin Bunz; Friederike Grevenkamp; Felix Kommoss; Jana Pasternak; Sabine M Arbabi; Markus Wallwiener; Annette Staebler; Sigurd F Lax; Sara Y Brucker; Florin-Andrei Taran
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-14       Impact factor: 4.553

Review 2.  Should Endometrial Cancer Treatment Be Centralized?

Authors:  Vincenzo Dario Mandato; Andrea Palicelli; Federica Torricelli; Valentina Mastrofilippo; Chiara Leone; Vittoria Dicarlo; Alessandro Tafuni; Giacomo Santandrea; Gianluca Annunziata; Matteo Generali; Debora Pirillo; Gino Ciarlini; Lorenzo Aguzzoli
Journal:  Biology (Basel)       Date:  2022-05-18

3.  L1CAM: amending the "low-risk" category in endometrial carcinoma.

Authors:  Felix Kommoss; Friedrich Kommoss; Friederike Grevenkamp; Anne-Kathrin Bunz; Florin-Andrei Taran; Falko Fend; Sara Y Brucker; Diethelm Wallwiener; Birgitt Schönfisch; Karen Greif; Sigurd Lax; Annette Staebler; Stefan Kommoss
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-30       Impact factor: 4.553

4.  Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.

Authors:  Tomasz Banas; Kazimierz Pitynski; Krzysztof Okon; Aleksandra Winiarska
Journal:  BMC Cancer       Date:  2018-04-13       Impact factor: 4.430

5.  A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?

Authors:  Simone Marnitz; Till Walter; Birgid Schömig-Markiefka; Tobias Engler; Stefan Kommoss; Sara Yvonne Brucker
Journal:  Cancers (Basel)       Date:  2020-09-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.